v3.25.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Current assets    
Cash and cash equivalents $ 7,141 $ 8,836
Accounts receivable   268
Research and development tax credit receivable 519 610
Prepaid expenses and other current assets 849 811
Total current assets 8,509 10,525
Property, plant and equipment, net 269 455
Right-of-use assets, net 120 285
Other assets, non-current 6 7
Total assets 8,904 11,272
Current liabilities    
Accounts payable and accrued expenses 1,791 1,178
Lease liabilities, current 47 230
Other current liabilities 450 360
Total current liabilities 2,288 1,768
Lease liabilities, non-current 25 19
Warrant liability   1,372
Total liabilities 2,313 3,159
Commitments and contingencies (Note 7)
Stockholders' equity:    
Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized, 856 and 13,765 shares issued and outstanding, at December 31, 2024 and December 31, 2023, respectively
Common stock, par value $0.0001 per share, 300,000,000 shares authorized, 3,590,217 and 889,668 shares issued and outstanding, at December 31, 2024 and December 31, 2023, respectively
Additional paid-in capital 122,316 104,757
Accumulated other comprehensive loss (1,105) (1,578)
Accumulated deficit (114,620) (95,066)
Total stockholders' equity 6,591 8,113
Total liabilities and stockholders' equity $ 8,904 $ 11,272

Source

HTML PDF
ZIP